Fused FDG–PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen
- 6 August 2010
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 22 (3) , 671-680
Abstract
Background: Spleen and liver assessment for occult involvement of Hodgkin's lymphoma (HL) challenges current staging procedures. Patients and methods: We prospectively evaluated event-free survival (EFS) in 103 HL patients staged with fused 2-[fluorine-18]fluoro-2-deoxy-D-glucose–positron emission tomography (FDG–PET)/contrast-enhanced computed tomography (CT) to identify those at greatest risk for abdominal relapse. The EFS of this series was compared with that of a historical cohort of 100 HL patients staged with separate FDG–PET and diagnostic CT acquisitions. Results: Thirty-one of the 103 patients staged with FDG–PET/contrast-enhanced CT were found to have spleen involvement and 10 patients liver involvement, whereas 14 of the 100 patients staged with separate procedures were found to have spleen involvement and 3 patients liver involvement. There were significantly more intensive treatments (six courses of anthracycline-containing chemotherapy and spleen radiation) in the fused PET/CT group than in the historical cohort (P ≤ 0.04). At a median follow-up of 27 months, five events occurred in the fused PET/CT group (HL relapse, 4 patients; carcinoma, 1 patient) and 19 events in the historical cohort (HL relapse, 18 patients; acute promyelocytic leukemia, 1 patient). Ten of the 18 relapses in the historical cohort were localized in the spleen and/or liver area. None of the four relapses in the fused PET/CT group was localized below the diaphragm. Thus, FDG–PET/contrast-enhanced CT-guided treatment resulted in a 95% EFS, whereas separate FDG–PET and diagnostic CT-guided treatment resulted in an 81% EFS (P = 0.002). Conclusion: FDG–PET/contrast-enhanced CT is an accurate frontline single imaging diagnostic tool enabling effective tailored treatment in HL patients.Keywords
This publication has 27 references indexed in Scilit:
- Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-upHaematologica, 2009
- CT and 18F-FDG PET for Noninvasive Detection of Splenic Involvement in Patients with Malignant LymphomaAmerican Journal of Roentgenology, 2009
- The role of FDG-PET scans in patients with lymphomaBlood, 2007
- Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imagingBritish Journal of Radiology, 2007
- Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in LymphomaJournal of Clinical Oncology, 2007
- Randomized comparison of consolidation radiationversusobservation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scansLeukemia & Lymphoma, 2007
- PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2005
- Accuracy of Whole-Body Dual-Modality Fluorine-18–2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography and Computed Tomography (FDG-PET/CT) for Tumor Staging in Solid Tumors: Comparison With CT and PETJournal of Clinical Oncology, 2004
- Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical TrialJournal of Clinical Oncology, 2002
- Detection of liver involvement in Hodgkin's diseaseJournal of Surgical Oncology, 1988